Trial Profile

A Phase 1 Dose-Escalation Study of Oral ARRY-438162 in Patients With Advanced Solid Tumors Followed by an Expansion Cohort in Patients With Advanced or Metastatic Biliary Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary)
Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Array BioPharma

22 May 2018 Results (n=28) assessing the tolerability, pharmacokinetics, and pharmacodynamics of ARRY 162 in patients with advanced solid tumours, followed by expansion cohorts in patients with advanced or metastatic biliary cancer and in patients with KRAS-mutant and BRAF-mutant colorectal cancer, were published in the Investigational New Drugs.
02 Feb 2017 Results published in the British Journal of Cancer
01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com